https://www.taxtmi.com/notifications?id=133920 The 2020 amendment permits companies engaged in research and development of new vaccines, drugs and medical devices to undertake COVID-19 related R&D as CSR during financial years 2020-21 to 2022-23 if conducted in collaboration with institutes specified in Schedule VII and separately disclosed in the Annual CSR Report; it also omits the exclusion for activities in the normal course of business from rule 4(1) and makes specified textual deletions to rule 6(1). en-us Mon, 24 Aug 2020 00:00:00 +0530 Tue, 25 Aug 2020 09:48:00 +0530 TaxTMI RSS Generator https://www.taxtmi.com/notifications?id=133920 The 2020 amendment permits companies engaged in research and development of new vaccines, drugs and medical devices to undertake COVID-19 related R&D as CSR during financial years 2020-21 to 2022-23 if conducted in collaboration with institutes specified in Schedule VII and separately disclosed in the Annual CSR Report; it also omits the exclusion for activities in the normal course of business from rule 4(1) and makes specified textual deletions to rule 6(1). Notifications Companies Law Mon, 24 Aug 2020 00:00:00 +0530 https://www.taxtmi.com/notifications?id=133920